Brain Metastases of a Neuroendocrine Tumor Visualized by 68Ga-DOTATATE PET/CTHoberück, Sebastian, MD*; Michler, Enrico, MD*; Zöphel, Klaus, MD*; Platzek, Ivan, MD†; Kotzerke, Jörg, MD*; Brogsitter, Claudia, MD*Clinical Nuclear Medicine: January 2019 - Volume 44 - Issue 1 - p 50–52 doi: 10.1097/RLU.0000000000002341 Interesting Images Buy SDC Abstract Author InformationAuthors Article MetricsMetrics A 65-year-old woman with a long history of metastasized, highly differentiated (G1) neuroendocrine tumor of pancreatic origin presented for follow-up 68Ga-DOTATATE PET/CT after 7 peptide receptor radiotherapies. In the previous scan, she already had discrete intracranial tracer accumulations, which were massively progressive in the recent 68Ga-DOTATATE PET/CT 8 months later. This case illustrates that cerebral metastases in neuroendocrine tumors may occur many years after initial diagnosis, and their somatostatin receptor expression may rise within a few months to a level that reasonably justifies further peptide receptor radiotherapy. From the Departments of *Nuclear Medicine, and †Radiology, Universitätsklinikum der TU Dresden, Dresden, Germany. Received for publication June 27, 2018; revision accepted September 16, 2018. Conflicts of interest and sources of funding: none declared. Correspondence to: Sebastian Hoberück, MD, Department of Nuclear Medicine, Universitätsklinikum der TU Dresden, Fetscherstr. 74, 01307 Dresden, Germany. E-mail: Sebastian.Hoberueck@uniklinikum-dresden.de. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.